# A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

> **NCT00461006** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 176 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Actos
- **DRUG:** aleglitazar

## Key facts

- **NCT ID:** NCT00461006
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00461006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00461006, "A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00461006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*